Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The primary objective of the trial is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or NPM1-m acute leukemia based on safety and pharmacokinetics (PK).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 0-21 lat, ważący co najmniej 5 kg (większość uczestników poniżej 18 lat)
- •Ostra białaczka z mutacją KMT2A, NPM1 lub NUP98 w pierwszym lub kolejnym nawrocie
- •Choroba oporna na standardowe leczenie, w tym przeszczep szpiku
- •Potwierdzenie zmiany genetycznej przez centralną laboratorium
- •Stan ogólny wystarczający do aktywności (co najmniej 60% funkcjonalności)
- •Prawidłowa funkcja nerek - czyszczenie kreatyniny co najmniej 60 mL/min
Simplified criteria — AI translation
Trial details
- Minimum age
- 0 Years
- Maximum age
- 21 Years
- Last updated (source)
- October 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (20)
Children's Hospital Los Angeles
Los Angeles, United States
Children's Hospital Colorado
Aurora, United States
Children's Healthcare of Atlanta
Atlanta, United States
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, United States
Dana-Farber Cancer Institute
Boston, United States
Memorial Sloan Kettering Cancer Center - New York
New York, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
Children's Hospital of Philadelphia
Philadelphia, United States
St. Jude Children's Research Hospital
Memphis, United States
Texas Children's Hospital
Houston, United States
Seattle Children's Hospital
Seattle, United States
Sankt Anna-Kinderspital
Vienna, Austria
SickKids - The Hospital for Sick Children
Toronto, Canada
CHU de Nantes - Hôpital Femme-Enfant-Adolescent
Nantes, France
CHU de Reims - Hôpital Robert Debré
Paris, France
Ospedale Pediatrico Bambino Gesù
Roma, Italy
Fondazione IRCCS San Gerardo dei Tintori (Ospedale San Gerardo)
Monza, Italy
Prinses Maxima Centrum Kinderoncologie
Utrecht, Netherlands
Hospital Universitari Vall d'Hebrón
Barcelona, Spain
Hospital Infantil Universitario Niño Jesús
Madrid, Spain
Trial contact
Dr. Branko Cuglievan
Dr. Sarah Tasian, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.